Home 12th Biosimilars Congregation 2018

12th Biosimilars Congregation 2018

Press Release: December 15, 2017

12th Biosimilars Congregation 2018 will provide insight into the current state of play in the EU and stimulate debate, in a multi-stakeholder setting, on the vital role of biosimilar medicines in the sustainability of healthcare systems.
Boehringer Ingelheim, Teva Pharmaceuticals, Fresenius Kabi SwissBioSim, Takeda, Wockhardt, Glenmark, Lupin, BPCRCS, GE Healthcare, European Medicines Agency, Bioceros, Danish Generic and Biosimilar Medicines Industry Association (IGL), ValeriusBio, ZRx Outcomes Research , Norwegian Medicines Agency, NICE, Polpharma Biologics, NHS - NIHR Clinical Research Network, Sterne, Kessler, Goldstein & Fox , Generics Bulletin, Frontline Pharma Consulting, Purple Squirrel Economics ,Bristows, Arnold & Porter
Brexit and Biosimilars, Biosimilar strategies , Current market trends ,Biosimilars in Oncology, Current challenges and opportunities , Payer perspective, Biosimilar Interchangeability, CMC, Preclinical and clinical considerations , Impact of Technology, Gain in-depth knowledge on role of technology transfer , Impact on clinical practice, Production of biosimilar MAbs, Right investments & potentials, Latest developments in regulation ,
People from
Biopharmaceuticals/ Biotherapeutics, Follow on Biologics/Follow on Proteins/Biosimilars, Biologics/Biotechnology/ Biogenerics, Legal Affairs , Intellectual Property, Health Economics, Pricing and Reimbursement, Clinical Immunology, Principal Scientist, Chief Scientific Officer, Process Control and Analytical Technologies, Analytical Characterisation, Regulatory Compliance, Risk Management, Quality Affairs/ Quality Control, New Product Development, Process Science, Portfolio Management, Research & Development, Business Operations, Scientific Affairs, Commercial Affairs, Marketing.

Join this event which provides an important platform for Biosimilars stakeholders to discuss and share best practices in furthering Biosimilars development.

Notes to editors

For more information, please contact:

Visit the newsroom of: virtueinsight